← Back to the library
EducationJune 25, 2023 · 4 min read

Psilocybin Assisted Psychotherapy – Truly a Breakthrough?

What is Psilocybin?

Psilocybin Assisted Therapy: What to Know, with illustrative mushrooms in front of a softly blurred counseling room

What is Psilocybin?

Psilocybin, also known as magic mushrooms, is a psychedelic drug that has been illegal in most countries since the 1960’s. It has recently gained attention for use during psychotherapy. Studies have shown that it enhances therapy by putting the brain in a “plastic” or changeable state. This allows the therapy to have greater effect. The patient can also change thought processes quicker.

History of Psilocybin

Psilocybin was discovered in the 1950’s. Research was done at Harvard University for a time to determine whether it had medical application. The research was shut down because of the abuse of psilocybin in the popular culture of the time. It became illegal to distribute, possess, or store in the controlled substances act of 1970. Psilocybin was classified as a schedule I controlled substance. In the early 2000’s psilocybin began to be available in the United States for limited research purposes. It has since gained popularity as an augmentation to psychotherapy.

Psilocybin Mechanism of Action

Psilocybin is an agonist or activator of serotonin receptors. In a sense, it is like having more serotonin in the synaptic cleft. The synaptic cleft is the space between neurons where neurotransmitters interact. The levels of neurotransmitters in this space correlate to how we think and feel. Activating these serotonin receptors also puts the brain in a “plastic” or changeable state. This allows psychotherapy to work to significant effect.

Studies showing use of Psilocybin Assisted Psychotherapy

“Conclusions: Our preliminary results have shown that psilocybin exerts a rapid effect in reducing depressive symptoms on primary and secondary depression. The optimal dose of psilocybin may be 30-35mg/70kg or higher; future clinical trials are warranted for further evaluation on its effect.”

Li, N.-X., Hu, Y.-R., Chen, W.-N., & Zhang, B. (2022). Dose effect of psilocybin on primary and secondary depression: a preliminary systematic review and meta-analysis. Journal of Affective Disorders, 296, 26–34. https://doi-org.intermountain.proxy.liblynxgateway.com/10.1016/j.jad.2021.09.041

“Conclusion: Psilocybin has promising effects on the patients with depression/anxiety even after a single dose. Psilocybin is safe but the administration should be guided by a health professional to yield safe and positive outcomes.”

Al-Naggar, R. A., Alshaikhli, H., & Erlam, G. (2021). Effectiveness of Psilocybin on Depression: A Qualitative Study. Electronic Journal of General Medicine, 18(3), 1–7. https://doi-org.intermountain.proxy.liblynxgateway.com/10.29333/ejgm/10862

“Conclusions: The LSD data and our three prior psilocybin studies show that 5HT2A agonist hallucinogens provoke profound changes in consciousness due to decreased integrity of brain networks and a decrease in between network segregation found in resting state measures, leading to a more chaotic or "entropic" brain state. These effects may also explain the utility of these drugs in addiction and mood disorders. The psilocybin for depression findings suggest that psilocybin is a safe and effective treatment for severe depression.”

Carhart-Harris R. (2015). Results: Of a multi-modal neuroimaging study of LSD and a psilocybin for treatment-resistant depression clinical trial. Neuropsychopharmacology, 40, S91–S92. https://doi-org.intermountain.proxy.liblynxgateway.com/10.1038/npp.2015.324

“Patients with major depressive disorder who received two administrations of the psychedelic psilocybin as part of a psychotherapy regimen saw a rapid and lasting improvement in depression symptoms, a randomized open‐label trial has found. These findings extend results of research that have suggested antidepressant effects for psilocybin in patients with cancer and treatment‐resistant depression, the researchers stated.”

Study: Psilocybin enhances therapy in patients with major depression. (2021). Brown University Psychopharmacology Update, 32(2), 1–5. https://doi-org.intermountain.proxy.liblynxgateway.com/10.1002/pu.30675

Psilocybin positives

Psilocybin may be the best way to augment your psychotherapy. Few meds create that psychoplastogen effect. Imagine having to pay for fewer therapy sessions and being able to heal faster and more efficiently. Psilocybin in low doses has few side effects. You may need to be monitored during the therapy session but the antidepressant effects last for weeks or longer after the initial administration.

Psilocybin negatives

Psilocybin use is still very controlled. Only a few clinics are currently using it to augment therapy. Long-term side effects of psilocybin use have still not been fully determined. It may also be difficult to find insurance companies that are willing to pay for its use. There is greater access to other psychoplastogens such as ketamine.

Compass Pathways

One company called Compass Pathways is pioneering the use of psilocybin in psychotherapy. More information can be found at this link. https://compasspathways.com/our-work/about-psilocybin-therapy/

The Anxious Resistance Take

The use of psilocybin in this way is still new. Research still needs to be done and the laws need to catch up. There is a lot of promise here though. Its use to augment psychotherapy is a breakthrough as determined by the US FDA. It may take a few years, but I wouldn’t be surprised if psilocybin clinics start to pop up near you.

The Secret Behind Magic Mushrooms: Transforming Mental Healthcare

Watch on YouTube

Educational content—not medical advice.Find support resources →